Chiome Bioscience Starts Phase I Trial of ADCT-701 in Neuroendocrine Tumors

Published on 2024-07-29 at 23:03 - Modified on 2024-07-29 at 23:04

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Chiome Bioscience Inc.

Chiome Bioscience Inc. Announces Collaborative Exploratory Research Agreement with OmniAb, Inc	02-27	CI
Japan Stocks Rise as Wholesale Inflation Fuels Rate Hike Bets	02-13	MT
Chiome Bioscience, Ceinge Biotecnologie Report Cancer Immunotherapy Findings in Cell Death Discovery	02-12	MT
Chiome Bioscience Publishes Phase I Study Results for CBA-1205	01-21	MT
Chiome Bioscience Inc. Announces Publication on CBA-1205 Non-Clinical Data	12-19	CI
Chiome Bioscience Extends Master Services Agreement with Chugai Pharmaceutical	12-18	MT
Chiome Bioscience Inc. and Chugai Pharmaceutical Co., Ltd. Agree with Extension of the Master Services Agreement	12-18	CI
Chiome Bioscience Licenses Anti-CX3CR1 Antibody to Asahi Kasei Pharma	11-20	MT
Chiome Announces Exclusive Licensing Agreement for Anti-CX3CR1 Antibody	11-20	CI
Chiome Bioscience Starts Phase I Trial of ADCT-701 in Neuroendocrine Tumors	24-07-29	MT
Chiome Bioscience Inc. Announces Commencement of Dosing Therapeutic Antibody Drug Conjugate, ADCT-701 in Phase I Clinical Study	24-07-28	CI
Chiome Bioscience Inc. announced that it has received ¥8.2792 million in funding from Growth Capital Co., Ltd., Next Growth Co., Ltd.	24-07-21	CI
Chiome Bioscience Inc. announced that it expects to receive ¥8.2792 million in funding from Growth Capital Co., Ltd., Next Growth Co., Ltd.	24-07-04	CI
Chiome Bioscience Cancels License Agreements with ADC Therapeutics	24-03-31	MT
Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	24-02-13	CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	24-02-13	CI
Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-11-14	CI
Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Chiome Bioscience Inc. announced that it has received ¥13.49304 million in funding from Barclays Bank PLC (Tokyo Branch), Growth Capital, Inc.	23-07-19	CI
Chiome Bioscience Inc. announced that it expects to receive Â¥13.49304 million in funding	23-07-03	CI
Chiome Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI
Chiome Bioscience Inc. Provided Sales Guidance for 2023	23-02-14	CI
Henlius Biotech Terminates License Agreement for Chiome Bioscience's Tumor Drug	23-01-17	MT
Chiome Bioscience Inc. Announces Termination of the License Agreement for Anti-TROP-2 Antibody Development and Commercialization with Shanghai Henlius Biotech, Inc	23-01-17	CI